Top Markets
Coin of the day
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX
Κατάταξη σε μετοχές #21215
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical... Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Τιμή μετοχής
$7.51
Τελευταίος συγχρονισμός: 2026-08-21
Κεφαλαιοποίηση
$112.52M
Αλλαγή (1 ημέρα)
0.13%
Αλλαγή (1 έτος)
128.27%
Χώρα
US
Εμπόριο Cumberland Pharmaceuticals Inc. (CPIX)

Κατηγορία

Η τιμή CPIX με την κεφαλαιοποίηση του Β
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
CPIX
$7.51
Κεφαλαιοποίηση αγοράς του Cumberland Pharmaceuticals Inc.(CPIX)
Κεφαλαιοποίηση: $112.52M
Μέχρι το August 2026, η Cumberland Pharmaceuticals Inc. έχει χρηματιστηριακή αξία $112.52M. Αυτό καθιστά τη Cumberland Pharmaceuticals Inc. την 21215th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Cumberland Pharmaceuticals Inc. από 2009 έως 2026
CPIX σε σύγκριση με τα 5 πιο δημοφιλή stocks
Η τιμή για CPIX Το περιουσιακό στοιχείο B Η κεφαλαιοποίηση αγοράς του B Αποτελέσματα
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
$347,818 $112.52M
$5.211T +4,631,296.87%
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
$303,460 $112.52M
$4.547T +4,040,639.69%
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
$277,813 $112.52M
$4.162T +3,699,134.99%
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
$239,791 $112.52M
$3.593T +3,192,849.89%
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.
$186,401 $112.52M
$2.793T +2,481,938.22%